RecruitingNot ApplicableNCT07255755

Cereboost (American Ginseng Extract) and Brain Function

A Double Blind Randomised Clinical Study to Evaluate Attention Improvement in an Adult Population After Cereboost Intake

Sponsor

University of East Anglia

Enrollment

200 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Cognition Attention

Summary

The study will assess the immediate, short-term benefits of a single dose of a supplement containing 200mg of Panax quinquefolius (American Ginseng) on cognition (brain function) in healthy young adults. To understand the effect this product may have, the participants will complete a series of questionnaires and cognitive tests (tests of memory and brain function) at set intervals across a 6-hour period. Blood samples will also be collected to assess the impact of the study product on the participants.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria13

To be eligible for inclusion, the Participant must fulfil all the following criteria:
Be able to give written informed consent.
Be between 18-40 years, inclusive.
Depression Anxiety and Stress Scale scores (DASS-21):
Depression ≤9
Anxiety ≤7
Stress ≤14
Willing to refrain from alcohol consumption 24-hours prior to assessment visits.
Willing to refrain from caffeine consumption (including but not limited to energy drinks, soda, coffee…) on the morning of the assessment visit.
Non-smokers and non-vapers
Willing to consume the Study Product (SP).
Willing to attend the study visit in an overnight fasted state, having followed a low-polyphenol diet for 48 h.
Fluent in written and spoken English

Exclusion Criteria27

Participants will be excluded from the study if they meet any of the following criteria:
Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
Has food allergies or other issues with foods that would preclude intake of the Study Products.
Not willing to consume gelatine from bovine/porcine source
Has a BMI ≤18.5 or ≥30kg/m2
Blood pressure \>140/90 mmHg
Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results.
Excluded health conditions include:
Cognitive disorders in the past 12 months.
Current or past history of a major neuropsychiatric disorder, including: bipolar disorder, schizophrenia and schizotypal personality disorder
Current or past history of a major neurological condition.
Gastrointestinal disorders (e.g. IBS/IBD)
ADHD (attention deficit hyperactivity disorder)
Learning disabilities and difficulties
Current, uncorrected, vision or hearing impairment
Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:
Anti-psychotics
Anti-coagulants (including Warfarin)
Anti-platelets (including Aspirin and Clopidogrel)
Sedatives
Monoamine Oxidase Inhibitors (MAOIs)
Taking any dietary supplements and unwilling to stop for two weeks prior to and for the duration of participation in the study
Current or history of drug or alcohol abuse
Current or history of: HIV, kidney disease, liver or biliary disorders, cancer, cardiovascular disease, pulmonary disease (chronic respiratory trouble)
Planned surgery within 2 weeks of their participation in the study
Do not agree to the GP being contacted about participation and screening results
Participated in any other cognitive trials within the last month